Last 12 months
Inside the activity.
0 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 6 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2019 Filed Mar 8, 2019 02:44 UTC |
Mullennix StephenChief Operating Officer
|
SaleOrdinary Shares | 2,804 | $37.30 | $104,589.20 |
DisclosureSEC source: 0001209191-19-017932 · doc4.xml · nonDerivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,230 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| February 14, 2019 Filed Mar 8, 2019 02:44 UTC |
Mullennix StephenChief Operating Officer
|
Exercise / conversionOrdinary Shares | 7,034 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-017932 · doc4.xml · nonDerivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| February 06, 2019 Filed Mar 22, 2019 23:41 UTC |
Cohen Fred EDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001209191-19-021091 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 15,000 shares Expires 2027-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 6.25% of the ordinary shares underlying the stock option vested on each of August 15, 2017, November 15, 2017 and February 15, 2018; 31.25% of the shares vested on May 15, 2018, and the remaining shares vest in 8 equal quarterly installments thereafter. Read SEC document |
| February 06, 2019 Filed Mar 22, 2019 23:41 UTC |
Cohen Fred EDirector
|
Exercise / conversionOrdinary Shares | 15,000 | $16.99 | $254,850.00 |
DisclosureSEC source: 0001209191-19-021091 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:24 UTC |
Schoenberg MarkChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005801 · doc4.xml · derivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 2,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F3 · derivative.expiration_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:24 UTC |
Schoenberg MarkChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001209191-19-005801 · doc4.xml · derivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Ordinary Shares · 7,500 shares Expires 2029-01-26 F1 · derivative.exercise_date: 33.33% of the shares underlying the stock option will vest on January 26, 2020 and 12.5% of the remaining shares will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:26 UTC |
Mullennix StephenChief Operating Officer
|
GrantRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005805 · doc4.xml · derivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F3 · derivative.expiration_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:26 UTC |
Mullennix StephenChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001209191-19-005805 · doc4.xml · derivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2029-01-26 F1 · derivative.exercise_date: 33.33% of the shares underlying the stock option will vest on January 26, 2020 and 12.5% of the remaining shares will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:25 UTC |
PFREUNDSCHUH PETER P.Chief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005803 · doc4.xml · derivative · entry 2 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F3 · derivative.expiration_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:25 UTC |
PFREUNDSCHUH PETER P.Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001209191-19-005803 · doc4.xml · derivative · entry 1 PFREUNDSCHUH PETER P. · CIK 0001585839 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2029-01-26 F1 · derivative.exercise_date: 33.33% of the shares underlying the stock option will vest on January 26, 2020 and 12.5% of the remaining shares will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 03, 2018 Filed Jan 10, 2019 01:25 UTC |
Barrett Elizabeth A.Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 317,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003174 · doc4.xml · derivative · entry 2 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,065 Underlying: Ordinary Shares · 317,065 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 33% of the RSUs will vest on January 3, 2020 and the remaining RSUs will vest 2.778% in equal monthly installments thereafter. F3 · derivative.expiration_date: 33% of the RSUs will vest on January 3, 2020 and the remaining RSUs will vest 2.778% in equal monthly installments thereafter. Read SEC document |
| January 03, 2018 Filed Jan 10, 2019 01:25 UTC |
Barrett Elizabeth A.Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 277,432 | $0.00 Strike: $47.57 | $0.00 |
DisclosureSEC source: 0001209191-19-003174 · doc4.xml · derivative · entry 1 Barrett Elizabeth A. · CIK 0001764157 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,432 Underlying: Ordinary Shares · 277,432 shares Expires 2029-01-03 F1 · derivative.exercise_date: 33% of the shares underlying the stock option will vest on January 3, 2020 and 2.778% of the remaining shares will vest in equal monthly installments thereafter. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 17:07 UTC |
ProQuest Investments IV, L.P.10% owner
ProQuest Associates IV LLC10% owner
Moorin Jay10% owner
SCHREIBER ALAIN10% owner
|
SaleOrdinary Shares, par value NIS 0.01 per share | 177,807 | $40.51 | $7,202,961.57 |
DisclosureSEC source: 0000932440-17-000088 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,242,031 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $40.50 to $41.01. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.direct: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:07 UTC |
ProQuest Investments IV, L.P.10% owner
ProQuest Associates IV LLC10% owner
Moorin Jay10% owner
SCHREIBER ALAIN10% owner
|
SaleOrdinary Shares, par value NIS 0.01 per share | 31,491 | $41.12 | $1,294,909.92 |
DisclosureSEC source: 0000932440-17-000088 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,419,838 F2 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $41.00 to $41.68. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.direct: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.